Orion Porfolio Solutions LLC Purchases 66,112 Shares of Kenvue Inc. $KVUE

Orion Porfolio Solutions LLC increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 30.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 283,590 shares of the company’s stock after buying an additional 66,112 shares during the quarter. Orion Porfolio Solutions LLC’s holdings in Kenvue were worth $5,936,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Trust Co. of Vermont raised its position in shares of Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after purchasing an additional 1,150 shares during the period. Truvestments Capital LLC acquired a new stake in Kenvue in the 1st quarter valued at $37,000. First Pacific Financial bought a new stake in Kenvue during the 2nd quarter valued at $54,000. Ransom Advisory Ltd acquired a new position in Kenvue during the first quarter worth $56,000. Finally, UMB Bank n.a. lifted its stake in shares of Kenvue by 22.3% in the second quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock valued at $60,000 after buying an additional 521 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Edward Jones cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. Jefferies Financial Group lowered their price objective on Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Evercore ISI set a $18.00 target price on Kenvue in a report on Tuesday, October 28th. Finally, Redburn Partners set a $22.00 target price on Kenvue in a research report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $20.23.

Kenvue Trading Down 0.8%

NYSE:KVUE opened at $17.20 on Tuesday. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The firm has a 50-day moving average price of $16.23 and a two-hundred day moving average price of $19.01. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The firm has a market cap of $32.94 billion, a price-to-earnings ratio of 22.93 and a beta of 0.59.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The company’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date was Wednesday, November 12th. Kenvue’s dividend payout ratio is 110.67%.

Insider Activity

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the transaction, the director directly owned 27,307,632 shares in the company, valued at $474,333,567.84. This trade represents a 13.27% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.17% of the stock is currently owned by corporate insiders.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.